-
-
An outbreak of highly drug-resistant S. enterica Serotype Typhimurium which was resistant to all drugs tested was first identified in 2 young boys in 2004 in Minnesota and North Carolina who had been in contact with pet mice.
-
Treatment of chronic Hepatitis B is directed at suppressing viral replication, reducing hepatitis (necroinflammatory) activity, slowing progression of fibrotic disease, inducing loss of HBeAg with seroconversion to anti-HBe, and rendering patients noninfectious.
-
Uk-427,857 (Maraviroc) is an investigational small-molecule HIV entry inhibitor that binds to the CCR5 chemokine receptor on the surface of T-cells. This chemokine receptor is normally the receptor for the chemokines MIP-1 alpha and RANTES.
-
Male sexual partners of women with vaginal trichomoniasis were tested, using urethral and urine culture, as well as urine polymerase chain reaction (PCR), for evidence of infection with this flagellated protozoan.
-
Pronovost and colleagues conducted a multi-hospital cohort study aimed at reducing the rate of catheter-related bloodstream infections (CRBSIs) in ICUs. The intervention focused on increasing adherence to evidence-based CDC recommendations for catheter insertion.
-
In a multicenter international open-label study, patients with proven or probable invasive aspergillosis (IA) that was refractory to standard antifungal therapy or who were intolerant to such therapy were treated with posaconazole in a total daily amount of 800 mg administered in divided doses.
-
Is Holding NSAIDs Prior to Surgery Rational?; Low-Dose Aspirin: Men vs Women; FDA Actions
-
In vitro resistance to daptomycin associated with clinical failure during treatment for MRSA infection has not been well documented. In vitro resistance to daptomycin is uncommon, de novo-resistant clinical isolates have not yet been reported, and the incidence of resistance, occurring during treatment is believed to be very low. The mechanism of resistance is not even known.
-
This article evaluates a mass immunization program with recombinant cholera-toxin B subunit, killed whole cell (rBS-WC) cholera vaccine in Beira, Mozambique, a city where seroprevalence of HIV infection is 20-30%.